DC-SIGN/CD209a Activators, in this context, refer to a group of chemical compounds that indirectly influence the functional activity of DC-SIGN/CD209a, a critical receptor on dendritic cells involved in pathogen recognition and antigen presentation. Compounds like Chloroquine and Ammonium Chloride, known for their roles in modulating endosomal pH, could enhance DC-SIGN/CD209a activity by affecting the receptor's ligand-binding ability and antigen processing mechanisms. Similarly, Monodansylcadaverine and Dynasore, which impact lysosomal activity and endocytic trafficking respectively, may augment the receptor's role in antigen presentation by altering intracellular trafficking routes. Chemicals that influence cellular membranes and cytoskeletal arrangements, such as Methyl-β-cyclodextrin, Filipin III, and Cytochalasin D, can also have indirect effects on DC-SIGN/CD209a activity. By altering membrane microdomains or disrupting lipid rafts, these compounds can affect receptor localization and function, potentially enhancing the receptor's ability to mediate endocytosis and subsequent antigen presentation.
Calcium channel blockers like Nicardipine, and microtubule-affecting agents such as Colchicine, may further modulate DC-SIGN/CD209a activity by influencing calcium-dependent processes and microtubule dynamics, crucial for dendritic cell function. Moreover, inhibitors of key signaling pathways, such as Wortmannin (a PI3K inhibitor) and Genistein (a tyrosine kinase inhibitor), could indirectly enhance DC-SIGN/CD209a function by modulating cellular signaling. This modulation can impact the maturation of dendritic cells and their capacity for antigen uptake and presentation. Nystatin, with its role in altering membrane cholesterol content, may also influence DC-SIGN/CD209a distribution and function, further impacting the receptor's immunological role. Collectively, these compounds, through their various mechanisms, facilitate the enhancement of DC-SIGN/CD209a-mediated functions, crucial in the immune response, particularly in the context of pathogen recognition and antigen processing.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
Ammonium Chloride, used to increase endosomal pH, could indirectly enhance DC-SIGN/CD209a activity by impacting receptor-mediated endocytosis and antigen processing. | ||||||
2-Hydroxypropyl-β-cyclodextrin | 128446-35-5 | sc-203461 sc-203461B sc-203461C sc-203461A | 1 g 100 g 500 g 5 g | $53.00 $620.00 $1989.00 $133.00 | 8 | |
Methyl-β-cyclodextrin, known for cholesterol depletion, can indirectly enhance DC-SIGN/CD209a activity by affecting membrane microdomain composition, potentially altering receptor function. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D, an actin polymerization inhibitor, can indirectly enhance DC-SIGN/CD209a activity by affecting cytoskeletal arrangements, impacting receptor-mediated endocytosis. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $118.00 $148.00 | 26 | |
Filipin III, a cholesterol-binding compound, may indirectly modulate DC-SIGN/CD209a activity by disrupting lipid rafts, affecting receptor localization and function. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore, a dynamin inhibitor, could indirectly enhance DC-SIGN/CD209a activity by altering endocytic trafficking, potentially impacting antigen processing and presentation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, may indirectly affect DC-SIGN/CD209a activity by altering signaling pathways involved in dendritic cell maturation and antigen presentation. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, can indirectly enhance DC-SIGN/CD209a activity by modulating cellular signaling pathways, potentially affecting receptor-mediated functions. | ||||||
Nystatin | 1400-61-9 | sc-212431 sc-212431A sc-212431B sc-212431C | 5 MU 25 MU 250 MU 5000 MU | $51.00 $129.00 $251.00 $3570.00 | 7 | |
Nystatin, an antifungal medication, may indirectly impact DC-SIGN/CD209a activity by altering membrane cholesterol content, affecting receptor distribution and function. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine, an anti-inflammatory compound, could indirectly enhance DC-SIGN/CD209a activity by affecting microtubule dynamics, potentially influencing antigen uptake and processing. | ||||||